GH Research PLC (GHRS) - Total Liabilities
Based on the latest financial reports, GH Research PLC (GHRS) has total liabilities worth $8.53 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore GH Research PLC operating cash flow efficiency to assess how effectively this company generates cash.
GH Research PLC - Total Liabilities Trend (2019–2025)
This chart illustrates how GH Research PLC's total liabilities have evolved over time, based on quarterly financial data. Check GHRS asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
GH Research PLC Competitors by Total Liabilities
The table below lists competitors of GH Research PLC ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Orezone Gold Corp
TO:ORE
|
Canada | CA$255.87 Million |
|
FPT Digital Retail JSC
VN:FRT
|
Vietnam | ₫18.58 Trillion |
|
Frequentis AG
VI:FQT
|
Austria | €256.53 Million |
|
Xinjiang Qingsong Building Materials and Chemicals Group Co Ltd
SHG:600425
|
China | CN¥2.81 Billion |
|
Permian Basin Royalty Trust
NYSE:PBT
|
USA | $6.49 Million |
|
Shenzhen Tagen Group Co Ltd
SHE:000090
|
China | CN¥51.66 Billion |
|
Amerant Bancorp Inc.
NYSE:AMTB
|
USA | $8.84 Billion |
|
Foosung
KO:093370
|
Korea | ₩499.67 Billion |
Liability Composition Analysis (2019–2025)
This chart breaks down GH Research PLC's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see how much is GH Research PLC worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 34.13 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.03 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.03 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how GH Research PLC's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for GH Research PLC (2019–2025)
The table below shows the annual total liabilities of GH Research PLC from 2019 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $8.53 Million | -8.53% |
| 2024-12-31 | $9.32 Million | +27.14% |
| 2023-12-31 | $7.33 Million | +61.28% |
| 2022-12-31 | $4.55 Million | +65.37% |
| 2021-12-31 | $2.75 Million | +1017.48% |
| 2020-12-31 | $246.00K | +136.54% |
| 2019-12-31 | $104.00K | -- |
About GH Research PLC
GH Research PLC, together with its subsidiary, a clinical-stage biopharmaceutical company, engages in developing treatments for depression in the United States. Its lead product candidate is GH001, an inhalable mebufotenin product candidate, which is in phase 2b clinical trial for treating patients with treatment-resistant depression; and in phase 2a clinical trial for treating bipolar II disorde… Read more